{"filings":[{"id":787014,"accession_number":"0001674930-26-000028","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-06-01T23:07:35+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.","Median progression-free survival 6.7 months; median duration of response 7.4 months.","One-year overall survival rate 63.4% in target population.","Phase 3 study is planned based on these results.","Data cutoff April 16, 2026; presentation at ASCO 2026 Rapid Oral Abstract Session."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584037,"accession_number":"0001674930-26-000025","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-05-21T21:04:12+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.","Median DoR 7.4 months; 56% of responders still responding at Dec 20, 2025 cut-off; OS immature.","Favorable safety: mostly Grade 1-2 TRAEs; Grade 3-4 neutropenia, anemia, leukopenia; one Grade 5 pneumonia (Arm B).","Abstract #6020 presented at ASCO 2026 Rapid Oral Session on June 1, 2026 in Chicago.","Company notes historical standard-of-care offers ORR 5.8%-19.1% and PFS 2.3-3.7 months in R/M HNSCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443399,"accession_number":"0001193125-26-224147","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-05-14T20:27:52+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.","All four director nominees elected: Ming Hsieh, Linda Dong, Michael Nohaile, Regina Groves (each to serve until 2027 annual meeting).","Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 approved (24.5M for, 87K against).","Non-binding advisory vote on named executive officer compensation passed (19.8M for, 2.4M against, 45K abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94599,"accession_number":"0001193125-26-199061","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).","Revenue $71.1M; GAAP gross margin 30.2%, non-GAAP gross margin 32.3%.","Adjusted EBITDA loss of $15.2M in Q1 2026.","Cash, equivalents, restricted cash & marketable securities $604.7M; expects ~$106M tax refund.","Bought back ~2.6M shares for $40.1M in Q1; FY2026 revenue guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":71138000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107109,"accession_number":"0001674930-26-000012","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.","StrataDx acquired for ~$13.5M cash; Bako Diagnostics assets acquired for ~$43.4M cash.","Acquisition includes lease assignment for 29,099 sq ft lab/office in Alpharetta, GA through July 2032.","Advisors: Piper Sandler and Mintz Levin for Fulgent; EV Health Partners and Latham & Watkins for sellers.","Transaction originally announced Dec 22, 2025; closed March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107108,"accession_number":"0001193125-26-079152","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.","GAAP net loss $23.4M ($0.76 loss per share) in Q4; full-year GAAP loss $60.5M ($1.97 per share).","Non-GAAP net income $5.2M ($0.16 per share) in Q4; full-year non-GAAP income $13.2M ($0.42 per share).","Cash, equivalents, restricted cash, and marketable securities totaled $705.5M at year-end, plus $106.3M anticipated tax refund.","Adjusted EBITDA loss of $4.5M in Q4 and $9.4M for full year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":322671000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123445,"accession_number":"0001193125-25-328747","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.","Deal expected to close in first half 2026; subject to regulatory approvals and customary conditions.","Adds anatomic pathology, proprietary PCR tests, nationwide sales team, and CLIA/CAP labs in GA and MA.","Fulgent plans to leverage AI and digital pathology (Eziopath) to improve efficiency at acquired labs.","Acquisition funded from cash on hand; Fulgent notes organic double-digit growth in lab services business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123444,"accession_number":"0001193125-25-271006","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q3 revenue $84.1M (+17% YoY), raises FY guidance, non-GAAP EPS $0.14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $84.1M, up 17% YoY; raised full-year 2025 revenue guidance to $325.0M.","GAAP net loss $6.6M ($0.21/share); non-GAAP net income $4.5M ($0.14/share).","Full-year EPS guidance raised: GAAP loss ~($1.70)/share, non-GAAP income $0.30/share.","Adjusted EBITDA $0.7M; GAAP gross margin 42.2%, non-GAAP 44.3%.","Cash and short-term investments $787.7M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":239335000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123443,"accession_number":"0001193125-25-242917","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulgent reports Phase 2 FID-007 combo data: 51% ORR, PFS 7.8 months in R/M HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Phase 2 data for FID-007 + cetuximab in 1L-2L R/M HNSCC; 39 patients randomized.","Overall ORR 51% (75 mg/m2: 44%, 125 mg/m2: 59%); median PFS 7.8 months vs historical 2.3 months.","Treatment-related SAE rate 6%; no grade 3+ peripheral neuropathy; common grade 3+ events include lymphopenia (19%) and neutropenia (17%).","Data presented at ESMO 2025 on October 20; optimal dose to be determined after data maturation.","CEO Ming Hsieh cites steady advancement of FID-007 and strong momentum in precision diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140113,"accession_number":"0000950170-25-101103","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q2 core revenue $81.7M (+16% YoY); raises FY2025 guidance to $320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue $81.7M, up 16% YoY; total revenue $81.8M.","GAAP net loss $19.0M ($0.62 per share) includes one-time charge; non-GAAP net income $2.1M ($0.07 per share).","Adjusted EBITDA loss of $3.0M.","Raising full-year 2025 core revenue guidance to $320M.","Cash and investments $777.5M at June 30; repurchased ~130k shares for $2.2M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":155266000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157759,"accession_number":"0000950170-25-072676","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulgent Genetics elects directors, ratifies auditor, approves say-on-pay at 2025 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Ming Hsieh (19.3M for), Michael Nohaile (16.0M for), Regina Groves (14.3M for), Linda Marsh (13.8M for).","Deloitte & Touche ratified as independent auditor for FY2025 with 25.2M votes for, 0.1M against.","Non-binding advisory vote on executive compensation approved: 16.3M for, 3.8M against, 60k abstain.","Approximately 82% of eligible shares (25.3M of 30.9M) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157758,"accession_number":"0000950170-25-062257","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 core revenue $73.5M (+16% YoY); GAAP loss $0.37/share; reiterates FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue of $73.5M, up 16% YoY; GAAP net loss of $11.5M ($0.37 loss per share).","Non-GAAP income of $1.2M ($0.04 per share); Adjusted EBITDA loss of $2.9M.","Reiterates full-year 2025 core revenue guidance of $310M.","Cash and investments $814.6M ($26.60 per share); repurchased ~516k shares for $8.7M in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":73463000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176129,"accession_number":"0000950170-25-029510","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.","GAAP net loss of $42.7M ($1.41 per share) for FY 2024; non-GAAP income $15.0M ($0.49 per share).","Q4 2024 total revenue $76.2M; core revenue up 14% to $76.0M; GAAP loss $5.9M, non-GAAP income $1.2M.","Ended 2024 with $828.6M cash & investments ($26.87/share); cash from ops $21.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":283470000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193033,"accession_number":"0000950170-24-123681","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.","GAAP net loss $14.6M ($0.48 per share); non-GAAP net income $9.4M ($0.31 per share).","Adjusted EBITDA income $0.4M; cash and marketable securities $815.4M.","Reiterated FY2024 core revenue guidance of $280M; improved EPS guidance for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":207256000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209395,"accession_number":"0000950170-24-089587","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q2 core revenue $70.2M (+5% YoY); GAAP loss $0.29/share improves EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.0M; core revenue $70.2M (+5% YoY).","GAAP net loss $8.7M ($0.29 per share); Non-GAAP income $4.7M ($0.15 per share).","Adjusted EBITDA loss $727K; cash from ops $4.3M; cash and investments $837.9M.","Reiterates FY2024 core revenue guidance $280M; improves EPS guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":135513000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227414,"accession_number":"0000950170-24-061120","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulgent Genetics announces 2024 annual meeting voting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh (votes for ranged ~15.8M to 20.0M).","Ratification of Deloitte & Touche as auditor for FY2024 approved with 24.2M votes for.","Advisory vote on executive compensation approved with 19.8M votes for.","Approximately 82% of eligible shares (24.5M of 29.9M) present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227413,"accession_number":"0000950170-24-052481","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 2024 core revenue $63.2M (+1% YoY), GAAP loss $0.45/share, reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $64.5M; core revenue $63.2M (+1% YoY); FY2024 core revenue guidance reiterated at $280M.","GAAP net loss $13.5M ($0.45 diluted loss per share); Non-GAAP loss $269K ($0.01 per share).","Adjusted EBITDA loss $3.2M; cash from operations $7.3M in Q1.","Cash, cash equivalents, and marketable securities $846.2M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":64485000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}